熱門資訊> 正文
Neurobo Pharmaceuticals与Mthera Pharma签署独家许可协议
2024-07-30 20:51
- NeuroBo Pharmaceuticals (NASDAQ:NRBO) announced the signing of an exclusive license agreement, providing MThera Pharma Co with the rights to NB-01 for the treatment of painful diabetic neuropathy.
- The agreement allows MTHERA to conduct research and clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States and South Korea, for the future commercialization of NB-01.
- Financial terms of the agreement were not disclosed.
- Source: Press Release
More on NeuroBo Pharmaceuticals
- NeuroBo Pharma prices private placement and direct offering to raise up to $70M
- NeuroBo says DA-1241, Wegovy combo shows potential in treating MASH
- Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals
- Historical earnings data for NeuroBo Pharmaceuticals
- Financial information for NeuroBo Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
